Skip to content

BioNTech Investor Relations company blog

BioNTech presents positive phase 1/2 data for CAR-T cell therapy candidate

investors.biontech.de

Read on investors.biontech.de → Discuss on HN (95) Archived copy

Points: 232
HN comments: 95
Submissions: 1
Cited by: 0 commenters

Science & Space Tech Industry & Business 2023

On Hacker News

Submitted	Title on HN	Points	Comments
Oct 24, 2023	BioNTech presents positive phase 1/2 data for CAR-T cell therapy candidate by doener	232	95

More from BioNTech Investor Relations

All 4 posts →

Pfizer and BioNTech Conclude Phase 3 Study of Covid-19 Vaccine Candidate

2020264 points171 comments Science & Space details

BioNTech-InstaDeep Early Warning System to Detect High-Risk SARS-CoV-2 Variants

2022149 points64 comments AI & Machine Learning details

BioNTech Plans to Address Infectious Diseases on the African Continent

2021103 points6 comments Science & Space details

Related posts from the same era

Mechanical Watch

Bartosz Ciechanowski20224,298 points704 commentscited by 59 details

Moon

Bartosz Ciechanowski20243,128 points290 comments details

Sound

Bartosz Ciechanowski20223,053 points238 commentscited by 8 details

Bicycle

Bartosz Ciechanowski20233,014 points399 commentscited by 14 details

GPS

Bartosz Ciechanowski20222,900 points320 commentscited by 32 details

Gordon Moore has died

Gordon and Betty Moore Foundation20232,594 points234 comments details